521 related articles for article (PubMed ID: 30255442)
1. Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.
Baldassari LE; Fox RJ
Drugs; 2018 Oct; 78(15):1549-1566. PubMed ID: 30255442
[TBL] [Abstract][Full Text] [Related]
2. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
3. Disease-Modifying Treatment in Progressive Multiple Sclerosis.
Ciotti JR; Cross AH
Curr Treat Options Neurol; 2018 Apr; 20(5):12. PubMed ID: 29627873
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
Nandoskar A; Raffel J; Scalfari AS; Friede T; Nicholas RS
Drugs; 2017 May; 77(8):885-910. PubMed ID: 28429241
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
6. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Samjoo IA; Worthington E; Haltner A; Spin P; Drudge C; Cameron C; Brennan R; Dahlke F; Adlard N
Curr Med Res Opin; 2021 Nov; 37(11):1933-1944. PubMed ID: 34384311
[TBL] [Abstract][Full Text] [Related]
7. [Disease-modifying treatment of secondary progressive multiple sclerosis].
Hoffmann O; Gold R
Nervenarzt; 2021 Oct; 92(10):1052-1060. PubMed ID: 33656569
[TBL] [Abstract][Full Text] [Related]
8. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
10. Involvement of cytotoxic Eomes-expressing CD4
Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
[TBL] [Abstract][Full Text] [Related]
11. [New therapeutic approaches in progressive multiple sclerosis].
Faissner S; Gold R
Fortschr Neurol Psychiatr; 2019 Nov; 87(11):653-671. PubMed ID: 31783427
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.
Shirani A; Okuda DT; Stüve O
Neurotherapeutics; 2016 Jan; 13(1):58-69. PubMed ID: 26729332
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
14. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
[TBL] [Abstract][Full Text] [Related]
15. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
16. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.
Ouallet JC
Rev Neurol (Paris); 2020 Jun; 176(6):500-504. PubMed ID: 32278541
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021.
Watson C; Thirumalai D; Barlev A; Jones E; Bogdanovich S; Kresa-Reahl K
Neurol Ther; 2023 Dec; 12(6):1961-1979. PubMed ID: 37682512
[TBL] [Abstract][Full Text] [Related]
18. [Disability Progression in SPMS Despite Therapeutic Intervention: Refractory SPMS].
Ochi H
Brain Nerve; 2022 May; 74(5):496-504. PubMed ID: 35589638
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing 'transition' to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians.
Hamdy E; Talaat F; Ramadan I; Marouf H; Hamdy MM; Sadallah H; El-Ashmawy GAH; Elsalamawy D; Said SM
Mult Scler Relat Disord; 2022 Apr; 60():103718. PubMed ID: 35279626
[TBL] [Abstract][Full Text] [Related]
20. Treatment trials in progressive MS--current challenges and future directions.
Koch MW; Cutter G; Stys PK; Yong VW; Metz LM
Nat Rev Neurol; 2013 Sep; 9(9):496-503. PubMed ID: 23897406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]